A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
CompletedPhase 2, Phase 3NCT02620020
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS). Secondary objectives of the study are to evaluate the efficacy of fasinumab compared to placebo as measured by: * Change from baseline in the Roland Morris disability questionnaire (RMDQ) total score * Change from baseline in the Patient Global Assessment (PGA) of Low Back Pain (LBP) score * Change from baseline in the average daily LBPI NRS score
Study details
- Official title
- A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain
- Conditions
- Interventions
- Drug: Fasinumab
- Drug: placebo
- Sponsor
- Regeneron Pharmaceuticals
- Start date
- 2016-01-26
- Primary completion
- 2017-02-03
- Sex
- All
- Age range
- from 35 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Canada, Czechia, Denmark, Estonia, Hungary, Poland, United States
- Total sites listed
- 74
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Key Inclusion Criteria: 1. Male or female ≥35 years of age at the screening visit 2. Clinical diagnosis of chronic moderate to severe LBP (nonradiculopathic)for ≥3 months 3. History of regular analgesic medication 4. History of inadequate pain relief or intolerance to analgesics used for chronic LBP 5. Willing to discontinue current pain medication Key Exclusion Criteria: 1. History of lumbosacral radiculopathy within the past 2 years 2. Evidence on baseline lumbar spine magnetic resonance imaging of potentially confounding conditions 3. Recent use of longer acting pain medications 4. Evidence of destructive arthropathy 5. Other medical conditions that may interfere with participation or accurate assessments during the trial
Canadian sites (2)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02620020